

REMARKS

Elections/Restrictions

Applicant elects with traverse to prosecute Group V, claims 6-13, drawn to diazines with two heterorings (where R¹ is diazine, or diazine fused to 5-membered heteroring), classified in class 544, subclass 236, 237, 353, and 354 with traverse.

In the specification, the paragraph beginning at page 1, line 2, has been amended to represent related U.S. priority applications.

Claims 1-5 and 14-20 have been canceled.

Date: July 17, 2003

Respectfully Submitted,

Joseph F. Reidy
Joseph F. Reidy
Attorney for Applicants
Reg. No. 39,340

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-7320
Fax: (858) 678-8233